Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Vaccinex Inc.
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2503 administered in combination with avelumab.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group, PA | Fayetteville, Arkansas, United States | — |
| University of California Los Angeles (UCLA) | Los Angeles, California, United States | — |
| Mayo Clinic | Jacksonville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Washington University School of Medicine | St Louis, Missouri, United States | — |
| Northwell Health Cancer Institute | Lake Success, New York, United States | — |
| University of Rochester | Rochester, New York, United States | — |
| Gabrail Cancer Center | Canton, Ohio, United States | — |
| Providence Portland Medical Center | Portland, Oregon, United States | — |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03268057